Introduction
Oxidative stress defines an imbalance between formation of reactive oxygen species (ROS) and antioxidative defence mechanisms. In view of the profound biological effects of ROS, in recent years numerous clinical and experimental studies focused on detection of signs of oxidative stress in renal patients. There is good evidence indicating that uraemia in general is associated with enhanced oxidative stress w1,2x, and treatment of uraemic patients with haemodialysis or peritoneal dialysis has been suggested to particularly contribute to oxidative stress and reduced antioxidant levels in these patients w3,4x. The latter may result from haemodialysis membrane-induced activation of macrophages on the surface of dialysis membranes during the dialysis session. Loss or deficiency of antioxidant activity (e.g. vitamin E deficiency) could also contribute to enhanced oxidative stress in uraemia.
In this issue of Nephrology Dialysis Transplantation, Klemm et al. w5x investigate erythrocyte antioxidant capacity and formation of oxygen radicals in haemodialysis patients using the electron paramagnetic resonance method. Klemm et al. identified glutathione peroxidase as the prominent, highly effective radicaleliminating system in erythrocytes. As long as this system was intact, there was no difference between haemodialysis patients and controls; only when glutathione peroxidase was inhibited did erythrocytes of haemodialysis patients show a significant delay in the elimination of free radicals, indicating a defect in the antioxidant forces outside the glutathione peroxidase system.
A series of reports over recent years demonstrated signs of increased oxidative stress in renal and haemodialysis patients. However, the significance of enhanced oxidative stress in renal patients remains to be further elucidated in clinical endpoint studies. The latter is of particular importance since in non-renal patients, studies using antioxidant treatments to prevent vascular and other diseases revealed equivocal effects w6-9x.
What generates oxidative stress?
It is generally accepted that ROS such as hydrogen peroxide (H 2 O 2 ) or hypochlorous acid (HOCl), and free radicals such as superoxide (O 2 À ), hydroxyl radical (OH), and nitric oxide (NO), are continuously formed in vivo w10x. Thus, detection of ROS per se does not yet define oxidative stress; however, in a situation where antioxidative defence mechanisms are attenuated, it is the imbalance between formation of ROS and defence mechanisms that creates oxidative stress. Renal sources for ROS are activated macrophages, vascular cells and various glomerular cells w1x. The balance between formation of ROS and antioxidative defence mechanisms depends on the activity of enzymes such as superoxide dismutases (SOD), catalase, NO-synthase, and, as emphasized in the study by Klemm et al. w5x , glutathione peroxidase. This balance, however, is rather fragile, difficult to predict, and strongly dependent on environmental conditions w10x, as illustrated in Figure 1 
Biological effects of oxidative stress
Formation of ROS is part of the unspecific defence system of an organism against, for example, bacteria and other microbes. However, ROS may also affect cells of the host organism, in particular at sites of inflammation. The latter plays a role in a variety of renal diseases, such as glomerulonephritis, acute or progressive renal failure, or tubulointerstitial nephritis w1,17x, contributing for example to proteinuria. ROS are also considered to contribute to the pathogenesis of ischaemia-reperfusion injury w18x. Furthermore, due to their impact on cell cycle regulation w19x, oxygen radicals may contribute to hypertrophy of tubular cells w20x. In the vascular system, the interaction of O 2 À with NO seems to be of major importance, particularly in the setting of hypercholesterolaemia, atherosclerosis, and in hypertension. The important endothelial vasodilator autacoid NO is inactivated by O 2 À w21x, and the reaction product peroxynitrite (ONOO À ) favours formation of even more ROS such as OH (Figure 1) w22x. Consequences for the vascular system are endothelial dysfunction and alterations of cellular turnover. Thus, for instance, atherogenic lipoproteins like LDL and Lp(a) not only undergo oxidative modification in the vascular wall w23x, but are also capable of enhancing generation of ROS via stimulation of NADHu NADPH-dependent oxidases in endothelial cells, smooth muscle cells, juxtaglomerular cells, and mesangial cells w24,25x. Enhanced O 2 À formation results in either cell proliferation or apoptotic death of endothelial cells, depending on the concentration and the time of exposure w25,26x.
Antioxidant studies in uraemia
As mentioned above, studies using antioxidant treatment to prevent vascular and other diseases revealed equivocal effects in non-renal patients w6-9x. Since renal patients live under particularly pro-oxidative conditions w3x, the question arises whether there may be particular benefit of antioxidant treatment for this subset of patients. Unfortunately, only a few antioxidant intervention studies with clinical endpoints have been published referring to renal patients. Two studies recently reported beneficial effects of vitamin E treatment on lipid metabolism, atherosclerosis, and cardiovascular disease (CVD) in haemodialysis patients. Mune et al. w27x used vitamin E coated cellulose membrane dialysers in end-stage renal disease patients for 2 years and measured oxidized LDL, LDLmalondialdehyde, and aortic calcification as an index for the progression of atherosclerosis. This treatment resulted in a significant reduction of LDL oxidation and reduced the progression of aortic calcification. In the SPACE study, the effect of high dose vitamin E supplementation (800 IUuday) on CVD was investigated in haemodialysis patients with pre-existing CVD w28x. In this high-risk population, vitamin E supplementation over 2 years resulted in a significant reduction of CVD end-points including myocardial infarction, without significant effects on total mortality and mortality from CVD. Thus, although the final word has not yet been spoken, there is already some evidence that antioxidant treatment is effective in the prevention of CVD in the high risk population of haemodialysis patients, emphasizing the clinical impact of elevated oxidative stress in these patients.
Conclusion
Our knowledge about stimuli and sources of oxidative stress, and about its role as an important cofactor contributing to endothelial dysfunction, inflammation, atherosclerosis and glomerulosclerosis has substantially increased over the last years. However, even though partial prevention of CVD by antioxidant treatment in haemodialysis patients could be achieved, no clinical end-point study using various antioxidant treatments was able to clearly show a beneficial effect on total mortality in non-renal or renal patients. Thus, a major task for the coming years will be to design effective antioxidant protocols and to analyse them in clinical intervention studies with hard end-points, including mortality, to prove whether the concept holds true.
